These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

158 related articles for article (PubMed ID: 21607551)

  • 1. A 13-week, multicenter, randomized, double-blind study of lumiracoxib in hip osteoarthritis.
    Schnitzer TJ; Dattani ID; Seriolo B; Schneider H; Moore A; Tseng L; Sallstig P; Rebuli R; Maxwell T
    Clin Rheumatol; 2011 Nov; 30(11):1433-46. PubMed ID: 21607551
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Lumiracoxib is effective in the treatment of osteoarthritis of the knee: a prospective randomized 13-week study versus placebo and celecoxib.
    Fleischmann R; Sheldon E; Maldonado-Cocco J; Dutta D; Yu S; Sloan VS
    Clin Rheumatol; 2006 Feb; 25(1):42-53. PubMed ID: 16132165
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Efficacy and tolerability of lumiracoxib in the treatment of osteoarthritis of the knee: a 13-week, randomized, double-blind comparison with celecoxib and placebo.
    Sheldon E; Beaulieu A; Paster Z; Dutta D; Yu S; Sloan VS
    Clin Ther; 2005 Jan; 27(1):64-77. PubMed ID: 15763607
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Long-term retention on treatment with lumiracoxib 100 mg once or twice daily compared with celecoxib 200 mg once daily: a randomised controlled trial in patients with osteoarthritis.
    Fleischmann R; Tannenbaum H; Patel NP; Notter M; Sallstig P; Reginster JY
    BMC Musculoskelet Disord; 2008 Mar; 9():32. PubMed ID: 18328090
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Evaluation of the patient acceptable symptom state in a pooled analysis of two multicentre, randomised, double-blind, placebo-controlled studies evaluating lumiracoxib and celecoxib in patients with osteoarthritis.
    Dougados M; Moore A; Yu S; Gitton X
    Arthritis Res Ther; 2007; 9(1):R11. PubMed ID: 17266764
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Efficacy and tolerability of lumiracoxib 100 mg once daily in knee osteoarthritis: a 13-week, randomized, double-blind study vs. placebo and celecoxib.
    Lehmann R; Brzosko M; Kopsa P; Nischik R; Kreisse A; Thurston H; Litschig S; Sloan VS
    Curr Med Res Opin; 2005 Apr; 21(4):517-26. PubMed ID: 15899100
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Efficacy and safety of four doses of lumiracoxib versus diclofenac in patients with knee or hip primary osteoarthritis: a phase II, four-week, multicenter, randomized, double-blind, placebo-controlled trial.
    Schnitzer TJ; Beier J; Geusens P; Hasler P; Patel SK; Senftleber I; Gitton X; Moore A; Sloan VS; Poór G
    Arthritis Rheum; 2004 Aug; 51(4):549-57. PubMed ID: 15334426
    [TBL] [Abstract][Full Text] [Related]  

  • 8. First-dose analgesic effect of the cyclo-oxygenase-2 selective inhibitor lumiracoxib in osteoarthritis of the knee: a randomized, double-blind, placebo-controlled comparison with celecoxib [NCT00267215].
    Wittenberg RH; Schell E; Krehan G; Maeumbaed R; Runge H; Schlüter P; Fashola TO; Thurston HJ; Burger KJ; Trechsel U
    Arthritis Res Ther; 2006; 8(2):R35. PubMed ID: 16469112
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Lumiracoxib is effective in the treatment of osteoarthritis of the knee: a 13 week, randomised, double blind study versus placebo and celecoxib.
    Tannenbaum H; Berenbaum F; Reginster JY; Zacher J; Robinson J; Poor G; Bliddal H; Uebelhart D; Adami S; Navarro F; Lee A; Moore A; Gimona A
    Ann Rheum Dis; 2004 Nov; 63(11):1419-26. PubMed ID: 15020310
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Long-term efficacy and safety of lumiracoxib 100 mg: an open-label extension of a 13-week randomized controlled trial in patients with primary osteoarthritis of the knee.
    Sheldon EA; Beaulieu A; Paster Z; Yu S; Rebuli R
    Clin Exp Rheumatol; 2008; 26(4):611-9. PubMed ID: 18799092
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Analgesic effectiveness of celecoxib and diclofenac in patients with osteoarthritis of the hip requiring joint replacement surgery: a 12-week, multicenter, randomized, double-blind, parallel-group, double-dummy, noninferiority study.
    Emery P; Koncz T; Pan S; Lowry S
    Clin Ther; 2008 Jan; 30(1):70-83. PubMed ID: 18343244
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A Randomized, Multicenter, Phase III Trial to Evaluate the Efficacy and Safety of Polmacoxib Compared with Celecoxib and Placebo for Patients with Osteoarthritis.
    Lee M; Yoo J; Kim JG; Kyung HS; Bin SI; Kang SB; Choi CH; Moon YW; Kim YM; Han SB; In Y; Choi CH; Kim J; Lee BK; Cho S
    Clin Orthop Surg; 2017 Dec; 9(4):439-457. PubMed ID: 29201297
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A 6-week, multicentre, randomised, double-blind, double-dummy, active-controlled, clinical safety study of lumiracoxib and rofecoxib in osteoarthritis patients.
    Stricker K; Yu S; Krammer G
    BMC Musculoskelet Disord; 2008 Sep; 9():118. PubMed ID: 18778469
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Efficacy and tolerability of lumiracoxib versus placebo in patients with osteoarthritis of the hand.
    Grifka JK; Zacher J; Brown JP; Seriolo B; Lee A; Moore A; Gimona A
    Clin Exp Rheumatol; 2004; 22(5):589-96. PubMed ID: 15485012
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Tramadol hydrochloride extended-release once-daily in the treatment of osteoarthritis of the knee and/or hip: a double-blind, randomized, dose-ranging trial.
    DeLemos BP; Xiang J; Benson C; Gana TJ; Pascual ML; Rosanna R; Fleming B
    Am J Ther; 2011 May; 18(3):216-26. PubMed ID: 20215961
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Lumiracoxib 400 mg compared with celecoxib 400 mg and placebo for treating pain following dental surgery: a randomized, controlled trial.
    Fricke J; Davis N; Yu V; Krammer G
    J Pain; 2008 Jan; 9(1):20-7. PubMed ID: 17933588
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Efficacy and safety of tanezumab added on to diclofenac sustained release in patients with knee or hip osteoarthritis: a double-blind, placebo-controlled, parallel-group, multicentre phase III randomised clinical trial.
    Balanescu AR; Feist E; Wolfram G; Davignon I; Smith MD; Brown MT; West CR
    Ann Rheum Dis; 2014 Sep; 73(9):1665-72. PubMed ID: 23852695
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Efficacy of lumiracoxib in osteoarthritis: a review of nine studies.
    Berenbaum F; Grifka J; Brown JP; Zacher J; Moore A; Krammer G; Dutta D; Sloan VS
    J Int Med Res; 2005; 33(1):21-41. PubMed ID: 15651713
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Lumiracoxib in the treatment of osteoarthritis, rheumatoid arthritis and acute postoperative dental pain: results of three dose-response studies.
    Schnitzer TJ; Gitton X; Jayawardene S; Sloan VS
    Curr Med Res Opin; 2005 Jan; 21(1):151-61. PubMed ID: 15881487
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A 2-week, multicenter, randomized, double-blind, placebo-controlled, dose-ranging, phase III trial comparing the efficacy of oxymorphone extended release and placebo in adults with pain associated with osteoarthritis of the hip or knee.
    Kivitz A; Ma C; Ahdieh H; Galer BS
    Clin Ther; 2006 Mar; 28(3):352-64. PubMed ID: 16750450
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.